Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Dec 27, 2016
Insider Transaction Report
Form 4
JENKINSON PAUL L
Chief Financial Officer
Transactions
- Award
Common Stock
2016-12-22+6,600→ 6,600 total - Award
Employee Stock Option (Right to Buy)
2016-12-22+24,200→ 24,200 totalExercise: $46.09Exp: 2026-12-22→ Common Stock (24,200 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.